ReviewCancers2025
Adenoid Cystic Carcinoma of the Breast: A Narrative Review and Update on Management.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Adenoid cystic carcinoma of the breast: report of the diagnosis and management of two cases.International journal of surgery case reports · 2026Article
- Ultrasound features and clinicopathologic correlations of breast adenoid cystic carcinoma: a retrospective observational study.Translational cancer research · 2026Article
- Adenoid Cystic Carcinoma of the Breast: Clinicopathological Features and Long-Term Outcomes from a 20-Year Retrospective Cohort.Oncology research · 2026Article
- Prognostic value of FDG PET/CT in special types of breast cancer with non-favorable histology.Discover oncology · 2025Article
- Real-world insights on a rare disease: adenoid cystic carcinoma of the breast.Ecancermedicalscience · 2025Article
- A Rare Case of Adenoid Cystic Breast Cancer: A Case Report and Literature Review.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rare breast malignancies represent a challenge for treatment decision making given the lack of evidence-based guidelines. As a particularly uncommon tumor, adenoid cystic carcinomas are especially challenging. Although, histopathologically, they share the same tumor molecular profile as hormone receptor-negative and HER2 nonamplified carcinomas with aggressive physiology, adenoid cystic carcinomas generally have a favorable prognosis. Thus, there is evidence to suggest that more aggressive treatment regimens may not provide better therapeutic effects. In this review, we discuss ACCB with the goal of highlighting pathophysiology, clinical features, and treatment strategies. Existing data support consideration for adjuvant radiation with the omission of axillary staging and systemic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.